Hostname: page-component-848d4c4894-mwx4w Total loading time: 0 Render date: 2024-07-03T21:57:37.960Z Has data issue: false hasContentIssue false

P0265 - Auricular acupuncture experience among dual diagnosis patients: Randomized controlled pilot clinical trial

Published online by Cambridge University Press:  16 April 2020

E. Goldstien
Affiliation:
Abarbanel Mental Health Center (Bat Yam), Affiliated With The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Y. Baruch
Affiliation:
Abarbanel Mental Health Center (Bat Yam), Affiliated With The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Y. Gimelfarb
Affiliation:
Abarbanel Mental Health Center (Bat Yam), Affiliated With The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Z. Natan
Affiliation:
Abarbanel Mental Health Center (Bat Yam), Affiliated With The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
S. Elwahidi
Affiliation:
Abarbanel Mental Health Center (Bat Yam), Affiliated With The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
E. Kaikov
Affiliation:
Abarbanel Mental Health Center (Bat Yam), Affiliated With The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The auricular acupuncture (AA) detoxification was first introduced in 1974. Over the past thirty years this technique has been extensively studied, expanded and improved. Unfortunately, there is no empirical evidence to recommend the use of AA for dual diagnosis patients (DDP). The absent data on the efficacy and safety of the AA leads to inappropriate use of this therapeutic intervention in DDP.

Methods:

Randomized controlled parallel groups clinical trial aimed to investigate the effectiveness and safety of AA in DDP for the management of both psychiatric and addiction issues. The study population group [10 AA tretments at least 20 minutes 4-5 times a week] comprised 10 subjects (9 males (90.0%), mean age 28.8 years (SD=5.7)). The control population group (without AA) comprised 3 subjects (3 males (100.0%), mean age 29.5 years (SD=7.8)). Antipsychotic efficacy was measured by CGI–Severity & CGI–Improvement scales, craving was measured by Drug-DALI and treatment compliance was measured by DAI-10.

Results:

There were no differences between the groups according to demographic and clinical measures at the beginning of the study. The mean DALI score change in study population was –3.7 (SD=3.9; p<.06), the mean DAI score change was 3.9 (SD=4.6; p<.06) in comparison to –6.0 (SD=4.2; NS) and 5.5 (SD=10.6; NS) in a control population, respectively. Were no differences in CGI-I (NS). There were no adverse events in both populations.

Conclusions:

There is a trend for effect of AA to craving decrease and a trend for effect to improvement of treatment-compliance in DDP.

Type
Poster Session I: Neuroleptics and Antipsychotics
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.